FIGURE 3.

Bortezomib/cyclophosphamide prior to bone marrow transplantation (BMT) reduces bone marrow B cells in sensitized recipients. A, Schematic of the experiment shown in B‐E. Four weeks after immunization with FVB splenocytes, NOD mice were treated with cyclophosphamide and bortezomib (CyBor) intravenously. Four days after CyBor treatment, bone marrow transplantation with 20 million FVB bone marrow cells (BMC) was done. Splenocytes and BMC were collected 5 d after BMT for analysis. Sera were collected before CyBor treatment and 5 d post‐BMT. Shown are cell counts of B cells and plasma cells in the bone marrow (panel B) and spleens (panel C) in mice given CyBor or vehicle. D, Sera were collected prior to immunization and 5 d post‐BMT, ie 9 d after CyBor treatment. Shown are mean fluorescence intensity (MFI) of donor‐specific antibodies (DSA)‐IgG Fc in the titrated sera from individual control (on the left) or CyBor treated mice (on the right). E, Shown are percentile changes at day 9 in MFI of DSA at the 1:25 dilution compared to pretreatment. Filled and empty symbols represent data collected in two separate experiments